We are a biotech company focused on the discovery and development of novel, fully human monoclonal antibodies for the prevention and treatment of serious bacterial and viral infections in the hospital setting.
Kenta Biotech is focusing on the discovery and development of innovative, fully human monoclonal antibodies for the life-saving treatment of patients with serious infectious diseases.
For the discovery of our monoclonal antibodies, we are using our proprietary MabIgX technology platform that enables the generation of an advanced class of fully human monoclonal antibodies that are expected to have superior safety and efficacy profiles.
We currently have one product candidate in clinical development and several product candidates in preclinical development. All our product candidates have been developed based upon our unique MabIgX technology.
The lead product candidate, KBPA101, is being developed for the treatment of life-threatening Pseudomonas aeruginosa infections in hospitalised patients. We have completed the clinical Phase I with this compound and will now advance the compound into Phase II proof-of-concept trials.
Our preclinical product candidates are targeting various bacterial and viral nosocomial infections.
At our headquarters in Berne, Switzerland, we currently employ a team of highly qualified and experienced scientists, clinical specialists, and technicians with a proven track record in the discovery and development of monoclonal antibodies. With this broad in-house expertise, Kenta Biotech is well positioned to address new targets and to advance the development of its lead product, KBPA101.
